SG168409A1 - Pyrazole derivatives as phosphodiesterase 4 inhibitors - Google Patents

Pyrazole derivatives as phosphodiesterase 4 inhibitors

Info

Publication number
SG168409A1
SG168409A1 SG200717031-9A SG2007170319A SG168409A1 SG 168409 A1 SG168409 A1 SG 168409A1 SG 2007170319 A SG2007170319 A SG 2007170319A SG 168409 A1 SG168409 A1 SG 168409A1
Authority
SG
Singapore
Prior art keywords
phosphodiesterase
inhibitors
pyrazole derivatives
compounds
inhibition
Prior art date
Application number
SG200717031-9A
Other languages
English (en)
Inventor
Allen Hopper
Erik Kuester
Robert Dunn
Richard Conticello
Original Assignee
Memory Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memory Pharm Corp filed Critical Memory Pharm Corp
Publication of SG168409A1 publication Critical patent/SG168409A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG200717031-9A 2003-04-18 2004-04-16 Pyrazole derivatives as phosphodiesterase 4 inhibitors SG168409A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46372503P 2003-04-18 2003-04-18

Publications (1)

Publication Number Publication Date
SG168409A1 true SG168409A1 (en) 2011-02-28

Family

ID=33310812

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200717031-9A SG168409A1 (en) 2003-04-18 2004-04-16 Pyrazole derivatives as phosphodiesterase 4 inhibitors

Country Status (12)

Country Link
US (3) US7226930B2 (zh)
EP (1) EP1631568A1 (zh)
JP (1) JP2006523719A (zh)
KR (1) KR20060005375A (zh)
CN (1) CN1809559B (zh)
AU (1) AU2004232973A1 (zh)
BR (1) BRPI0409888A (zh)
CA (1) CA2522687A1 (zh)
MX (1) MXPA05011200A (zh)
RU (1) RU2379292C2 (zh)
SG (1) SG168409A1 (zh)
WO (1) WO2004094411A1 (zh)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2211344B1 (es) * 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
JP2006523719A (ja) 2003-04-18 2006-10-19 メモリー・ファーマシューティカルズ・コーポレイション ホスホジエステラーゼ４抑制剤としてのピラゾール誘導体
ES2251866B1 (es) * 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) * 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
JP2008515990A (ja) 2004-10-13 2008-05-15 ピーティーシー セラピューティクス，インコーポレーテッド ナンセンス抑制のための化合物およびその使用方法
AU2005295753A1 (en) * 2004-10-15 2006-04-27 Memory Pharmaceuticals Corporation Pyrazole derivatives as phosphodiesterase 4 inhibitors
US7446210B2 (en) * 2004-10-26 2008-11-04 Janssen Pharmaceutica N.V. Factor Xa compounds
WO2007002559A1 (en) * 2005-06-27 2007-01-04 Exelixis, Inc. Pyrazole based lxr modulators
EP2218442A1 (en) 2005-11-09 2010-08-18 CombinatoRx, Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
CN101365700A (zh) 2005-11-15 2009-02-11 沃泰克斯药物股份有限公司 可用作激酶抑制剂的氮杂吲唑
WO2007123953A2 (en) * 2006-04-19 2007-11-01 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
KR100820246B1 (ko) * 2006-10-10 2008-04-07 한국화학연구원 1-(3,4-디알콕시벤질)-1ｈ-피라졸 화합물, 이의 제조방법및 이를 포함하는 천식 및 만성폐쇄성 폐질환을 포함한염증관련 질환, 관절염, 아토피 피부염, 암 및 뇌질환의치료 및 예방을 위한 약제학적 조성물
CN101616587A (zh) * 2006-12-05 2009-12-30 孙仲铭 吲唑化合物
ES2320954B1 (es) * 2007-03-02 2010-03-16 Laboratorio Almirall S.A. Nuevo procedimiento de preparacion de 3-metil-4-fenilisoxazolo (3,4-d)iridazin-7(6h)-ona.
CN102724877B (zh) * 2009-09-01 2015-05-13 凯特贝希制药公司 脂肪酸烟酸缀合物及其用途
USRE46608E1 (en) 2009-09-01 2017-11-14 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
DK2544679T3 (da) 2010-03-12 2019-07-22 Omeros Corp Pde10-inhibitorer og relaterede sammensætninger og fremgangsmåder
KR102385359B1 (ko) * 2010-11-08 2022-04-11 오메로스 코포레이션 Pde7 억제제를 사용한 중독 및 충동-조절 장애의 치료
WO2012123353A1 (en) * 2011-03-17 2012-09-20 Algiax Pharmaceuticals Gmbh Novel use of benzofuranylsulfonates
EP2907806A1 (en) 2014-02-14 2015-08-19 Universita Degli Studi Di Genova New compounds as selective PDE4D inhibitors
NZ630810A (en) 2014-04-28 2016-03-31 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
NZ630803A (en) 2014-04-28 2016-03-31 Omeros Corp Optically active pde10 inhibitor
US9879002B2 (en) 2015-04-24 2018-01-30 Omeros Corporation PDE10 inhibitors and related compositions and methods
WO2017079678A1 (en) 2015-11-04 2017-05-11 Omeros Corporation Solid state forms of a pde10 inhibitor
GB201616439D0 (en) * 2016-09-28 2016-11-09 Mironid Limited Compounds and uses
GB201805527D0 (en) 2018-04-04 2018-05-16 Mironid Ltd Compounds and their use as pde4 activators
EP3773562A1 (en) * 2018-04-05 2021-02-17 Universiteit Hasselt Selective pde4d inhibitors against demyelinating diseases
AR116754A1 (es) * 2018-10-18 2021-06-09 Sumitomo Chemical Co Compuesto de fenilpirazol y método para controlar fitoenfermedades

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0812654A (ja) * 1994-06-27 1996-01-16 Sankyo Co Ltd ４−ハロピラゾール−３−カルボン酸誘導体
WO1996041626A1 (en) * 1995-06-12 1996-12-27 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
WO2001040216A1 (en) * 1999-12-03 2001-06-07 Pfizer Products Inc. Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents
EP1251126A2 (en) * 2001-04-20 2002-10-23 Pharmacia Corporation Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
WO2003004480A2 (en) * 2001-07-02 2003-01-16 Novo Nordisk A/S Substituted piperazine and diazepanes as histamine h3 receptor agonists

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2413935A1 (de) * 1974-03-20 1975-10-16 Schering Ag 4-(polyalkoxy-phenyl)-2-pyrrolidone
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
DE2834114A1 (de) * 1978-08-01 1980-02-14 Schering Ag Polyalkoxyphenylpyrrolidone iii, verfahren zu ihrer herstellung und ihre verwendung
DD295358A5 (de) * 1989-06-28 1991-10-31 �����@������������������k�� Verfahren zur racemattrennung von 4-aryl-2-oxo-pyrrolidin-3-carbonsaeure-estern
US5935978A (en) * 1991-01-28 1999-08-10 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
PT100441A (pt) 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
AU2869092A (en) 1991-10-11 1993-05-03 Smithkline Beecham Corporation Heterocyclic 3-phenylpyrrolidin-2-ones, their preparation and use for the manufacture of a medicament for inhibiting tumor necrosis factor production
AU670949B2 (en) 1992-06-15 1996-08-08 Celltech Limited Trisubstituted phenyl derivatives as selective phosphodiesterase IV inhibitors
US5814651A (en) * 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
TW263495B (zh) 1992-12-23 1995-11-21 Celltech Ltd
WO1995026325A2 (en) * 1994-03-25 1995-10-05 Isotechnika Inc. Enhancement of the efficacy of drugs by deuteration
US6334997B1 (en) * 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
EP0758233B1 (en) 1994-04-21 2003-12-03 Schering Aktiengesellschaft Pde iv inhibitors for treating multiple sclerosis
GB9412383D0 (en) 1994-06-21 1994-08-10 Celltech Ltd Chemical compound
DE19518082A1 (de) * 1995-05-17 1996-11-21 Merck Patent Gmbh 4(-Arylaminomethylen)-2,4-dihydropyrazol-3-one
DE19601938A1 (de) 1996-01-12 1997-07-17 Schering Ag Neue Phosphodiesteraseinhibitoren
TR199802685T2 (xx) * 1996-06-25 1999-03-22 Pfizer Inc �kameli/katk�l� indazol t�revleri
JPH1072415A (ja) 1996-06-26 1998-03-17 Nikken Chem Co Ltd ３−アニリノ−２−シクロアルケノン誘導体
GB9622386D0 (en) * 1996-10-28 1997-01-08 Sandoz Ltd Organic compounds
CA2295106C (en) * 1997-06-24 2007-03-13 Nikken Chemicals Co., Ltd. 3-anilino-2-cycloalkenone derivatives
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
AU4308300A (en) * 1999-05-03 2000-11-17 Dr. Reddy's Research Foundation Pyrazoles having antiinflammatory activity
JP2001039954A (ja) * 1999-05-24 2001-02-13 Tomono Agrica Co Ltd ヘテロ環誘導体
US6372777B1 (en) * 1999-12-23 2002-04-16 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6258833B1 (en) * 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
GB0003257D0 (en) * 2000-02-11 2000-04-05 Darwin Discovery Ltd Heterocyclic compounds and their therapeutic use
EP1265861A2 (en) 2000-03-16 2002-12-18 Inflazyme Pharmaceuticals, Ltd. Benzylated pde4 inhibitors
EP1343528A2 (en) 2000-11-02 2003-09-17 Research Foundation of City University of New York Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4
US6495154B1 (en) * 2000-11-21 2002-12-17 Vivus Inc. On demand administration of clomipramine and salts thereof to treat premature ejaculation
DE60326069D1 (de) 2002-04-05 2009-03-19 Cadila Healthcare Ltd 4-(heterocyclyl)-benzenesulfoximin verbindungen zur behandlung entzündlicher erkrankungenen
UA79804C2 (en) 2002-07-03 2007-07-25 Janssen Pharmaceutica Nv Cck-1 receptor modulators
JP2006523719A (ja) 2003-04-18 2006-10-19 メモリー・ファーマシューティカルズ・コーポレイション ホスホジエステラーゼ４抑制剤としてのピラゾール誘導体

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0812654A (ja) * 1994-06-27 1996-01-16 Sankyo Co Ltd ４−ハロピラゾール−３−カルボン酸誘導体
WO1996041626A1 (en) * 1995-06-12 1996-12-27 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
WO2001040216A1 (en) * 1999-12-03 2001-06-07 Pfizer Products Inc. Heterocyclo-alkylsulfonyl pyrazole derivatives as anti-inflammatory/analgesic agents
EP1251126A2 (en) * 2001-04-20 2002-10-23 Pharmacia Corporation Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
WO2003004480A2 (en) * 2001-07-02 2003-01-16 Novo Nordisk A/S Substituted piperazine and diazepanes as histamine h3 receptor agonists

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
, RNS473299897, RNS473300355, RNS473302577, RNS473303036, WO1996041626 *
SYNTHESIS, STRUCTURE-ACTIVITY RELATIONSHIP, *

Also Published As

Publication number Publication date
KR20060005375A (ko) 2006-01-17
US20040229918A1 (en) 2004-11-18
RU2005135562A (ru) 2006-07-10
WO2004094411A1 (en) 2004-11-04
CA2522687A1 (en) 2004-11-04
RU2379292C2 (ru) 2010-01-20
CN1809559A (zh) 2006-07-26
CN1809559B (zh) 2010-06-02
EP1631568A1 (en) 2006-03-08
AU2004232973A1 (en) 2004-11-04
US7226930B2 (en) 2007-06-05
BRPI0409888A (pt) 2006-05-23
US7495017B2 (en) 2009-02-24
US20090221661A1 (en) 2009-09-03
MXPA05011200A (es) 2005-12-14
US20070203197A1 (en) 2007-08-30
JP2006523719A (ja) 2006-10-19

Similar Documents

Publication Publication Date Title
SG168409A1 (en) Pyrazole derivatives as phosphodiesterase 4 inhibitors
WO2007123953A3 (en) Phosphodiesterase 4 inhibitors
WO2004014913A3 (en) Derivatives of 2-trifluormethyl-6-aminopurine as phosphodiesterase 4 inhibitors
AU2003226572A1 (en) Heteroaryl substituted biphenyl derivatives as p38 kinase inhibitors
WO2004094375A3 (en) 4 - (3,4 - disubstituted phenyl) - pyrrolidin-2-one compounds as phosphodiesterase 4 inhibitors
WO2003072553A8 (en) N-aryl-2-oxazolidinone-5-carboxamides and their derivates and their use as antibacterials
DE602004024988D1 (de) 2-aminopyrimidin-derivate als raf-kinase-hemmer
ATE370142T1 (de) Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3
WO2002020489A3 (en) QUINOLINE INHIBITORS OF cGMP PHOSPHODIESTERASE
NO20043726L (no) Heteroarylforbindelser anvendelige som inhibitorer av GSK-3
WO2005061458A3 (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
WO2001087882A3 (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
IL161317A0 (en) 4-(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes
ATE413404T1 (de) Triazolopyrimidin derivate als inhibitoren von glycogen synthase kinase-3
WO2007105058A3 (en) Pyrazole compounds
WO2005058843A8 (en) Substituted 6-cyclohexylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
TNSN06405A1 (en) Quinazolinone derivatives useful as vanilloid antagonistes
WO2002085906A3 (en) Phthalazinones derivatives useful as pde4/7 inhibitors
WO2005077906A8 (en) Novel guanidinyl-substituted hydroxy-6-phenylphenenthridines as effective phosphodiesterase (pde) 4 inhibitors
HRP20050082A2 (en) 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors
NO20022232D0 (no) Imidazolforbindelser for anvendelse som inhibitorer for fosfodiesterase VII
TW200628153A (en) Novel compounds
WO2005028474A3 (en) Pyrazoloquinoline derivatives as chk-1 inhibitors
AU2001263278A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
EA200600100A1 (ru) Производные никотинамида, полезные в качестве ингибиторов pde4